Kathleen Sebelius, a director at Humacyte ($HUMA), sold 1,548 shares of the company on 09-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.6% of their shares. Following this trade, they now own 41,207 shares of Humacyte stock.
Humacyte Insider Trading Activity
Humacyte insiders have traded $HUMA stock on the open market 40 times in the past 6 months. Of those trades, 9 have been purchases and 31 have been sales.
Here’s a breakdown of recent trading of $HUMA stock by insiders over the last 6 months:
- LAURA E NIKLASON (President, CEO and Director) has traded it 15 times. They made 3 purchases, buying 5,634 shares and 12 sales, selling 2,960,256 shares.
- BRADY W DOUGAN has traded it 15 times. They made 3 purchases, buying 5,634 shares and 12 sales, selling 2,960,256 shares.
- KATHLEEN SEBELIUS has traded it 2 times. They made 0 purchases and 2 sales, selling 5,182 shares.
- DALE A. SANDER (CFO and Chief Corp. Deve. Off.) sold 39,389 shares.
- MICHAEL T. CONSTANTINO purchased 3,100 shares.
- HEATHER LEDBETTER PRICHARD (Chief Operating Officer) has traded it 4 times. They made 0 purchases and 4 sales, selling 191,511 shares.
- MAX N. WALLACE has traded it 2 times. They made 2 purchases, buying 8,005 shares and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Humacyte Hedge Fund Activity
We have seen 98 institutional investors add shares of Humacyte stock to their portfolio, and 44 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AIGH CAPITAL MANAGEMENT LLC removed 2,155,958 shares (-100.0%) from their portfolio in Q2 2024
- SIO CAPITAL MANAGEMENT, LLC removed 2,000,000 shares (-100.0%) from their portfolio in Q2 2024
- STATE STREET CORP added 1,895,529 shares (+66.1%) to their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC added 1,334,641 shares (+504.3%) to their portfolio in Q2 2024
- NUVEEN ASSET MANAGEMENT, LLC added 1,161,900 shares (+1420.8%) to their portfolio in Q2 2024
- WOODLINE PARTNERS LP added 848,534 shares (+inf%) to their portfolio in Q3 2024
- VOLORIDGE INVESTMENT MANAGEMENT, LLC added 687,296 shares (+inf%) to their portfolio in Q2 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Should I Buy $HUMA Stock?
The bull case for Humacyte Inc. ($HUMA) centers on its potential to capture a significant share of the lucrative vascular graft market, valued at over $90 billion, bolstered by promising clinical trial results and advantageous regulatory designations. The company's human-acellular vessel (HAV) shows notable clinical benefits, including lower infection rates and improved usability, enhancing its attractiveness compared to synthetic options. With positive outcomes like higher patency rates and reduced amputation risks, Humacyte's innovation positions it well for future growth and market viability. Conversely, the bear case highlights the ongoing operating losses that raise doubts about the timeline to profitability, alongside significant risks from competition, stringent regulatory requirements, and the possibility of unmet clinical trial expectations. These factors could hinder market adoption and sales growth, while potential delays and costs related to the commercialization of its bioengineered products may adversely impact Humacyte's revenue generation capabilities in the coming years.
Background on $HUMA Stock
Humacyte, traded as HUMA, is a biotechnology company focused on developing innovative human tissues for regenerative medicine applications. The company specializes in creating bioengineered tissue products, particularly human acellular vessels (HAVs), which are designed to serve as off-the-shelf solutions for a variety of medical needs, including vascular surgery, organ transplantation, and wound healing. Humacyte's technology harnesses the body's natural regenerative processes, allowing these engineered tissues to integrate with the patient's own biological systems. The goal is to improve patient outcomes by providing durable, biocompatible alternatives to traditional implants, thus enhancing the quality of life for individuals with significant medical challenges.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
